Meta-analysis On Efficacy And Safety Of Rifapentine And Rifampicin In Treatment Of Pulmonary Tuberculosis

Objective:To evaluate the effectiveness and safety of rifampicin and rifapentine on treating pulmonary tuberculosis through meta-analysis and to provide a more reliable and scientific evifence for rifapentine on the clinical treatment of pulmonary tuberculosis. Methods:We ellectrically search Wan Fang Data, Wei Pu Data,Chao Xing Data,PubMed,CNKI,SionMed and The Cochrane Library,the search key terms were:rifapentine,rifampicin,pulmonary tuberculosis,search the public published clinical randomized controlled trials on the treatment of pulmonary tuberculosis with rifampicin and rifapentine totally 18.All the collected studies were analyzed with meta-analysis method by Rev Man 5.3 software.Results:18 RCTs were involved,the total sample cases were 2784,with 1417 cases in the rifapentine treatment group,1367 cases in the rifampicin treatment group.The therapeutic effect index include cavity-closure rate,nidus-absorption rate,bacterium-sputum overcast rate and the OR values were respectively 1.54[95% CI=1.21～1.95],2.06[95% CI=1.31～3.24],2.30[95% CI(1.49-3.54)] the difference had a statistically significance(p<0.05).On safety, the rifampicin and rifapentine group had no significance in joint-pain merely(P>0.05),while in liver function abnormality、rash、 hematoidin、abnormality,decreased WBC、fever、proteinuria、gastrointestinal adverse reaction there had statistically significances(P<0.05).Conclusion:From the results,we can conclude that,compared with rifampicin, rifapentine have an advantage in treating pulmonary tuberculosis on cavity closure,nidus absorption,bacterium sputum overcast,less adverse reaction and better tolerance.The difference had a statistically significance,rifapentine are better than rifampicin on safety.